Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

188
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
188
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

248
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
248

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Linerixibat: First Approval.

Drugs·2026
Same author

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

Targeted oncology·2026
Same author

Guselkumab: Pediatric First Approval.

Paediatric drugs·2026
Same author

Taletrectinib: First Approval.

Drugs·2025
Same author

Trastuzumab Rezetecan: First Approval.

Drugs·2025
Same author

Correction to: Revakinagene Taroretcel: First Approval.

Molecular diagnosis & therapy·2025

相关实验视频

Updated: Jul 10, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K

莫蒂克萨福蒂德:首次获得批准

Sheridan M Hoy1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|November 23, 2023
PubMed
概括
此摘要是机器生成的。

莫蒂克萨福蒂德是一种新型CXCR4抑制剂,已获批用于在多发性骨髓瘤患者中调动造血干细胞 (HSC). 这一里程碑标志着干细胞移植和癌症治疗的重大进展.

更多相关视频

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

39.8K
Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation
03:49

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Published on: October 11, 2024

834

相关实验视频

Last Updated: Jul 10, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

39.8K
Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation
03:49

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Published on: October 11, 2024

834

科学领域:

  • 在瘤学瘤学.
  • 血液学 血液学 血液学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 莫蒂克萨福蒂德是一种选择性CXCR4抑制剂.
  • 它是为血液造血干细胞 (HSC) 调动和癌症治疗而开发的.

研究的目的:

  • 总结一下motixafortide的发展里程碑.
  • 为了突出其最近的FDA批准用于多发性骨髓瘤中HSC调动.

主要方法:

  • 对motixafortide的临床开发数据的审查.
  • 对监管机构提交和批准的分析.

主要成果:

  • 莫蒂克萨福蒂德于2023年9月11日在美国批准,与菲尔格拉斯蒂姆一起用于多发性骨髓瘤中HSC调动.
  • 在胰腺癌和急性髓性白血病中获得孤儿药物指定.

结论:

  • 莫蒂克萨福蒂德的批准代表了干细胞调动的重大进展.
  • 目前正在进行的试验针对状细胞疾病的基因疗法,扩大其治疗潜力.